A carregar...
Baseline Differences in Minor Lymphocyte Subpopulations may Predict Response to Fingolimod in Relapsing–Remitting Multiple Sclerosis Patients
AIMS: Fingolimod, oral treatment for relapsing–remitting multiple sclerosis (RRMS), is an agonist of sphingosine and its metabolite S1P that binds their receptors, blocking the egress of lymphocytes from lymph nodes. The aim of this study was immunomonitoring of minor peripheral lymphocyte subpopula...
Na minha lista:
| Publicado no: | CNS Neurosci Ther |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6492868/ https://ncbi.nlm.nih.gov/pubmed/27080413 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cns.12548 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|